Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | EZH2 | Q15910 | 10/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8739662 | 0.92 | MEN1 (0.60) | MEN1KMT2AEZH2GLACYP2C9 | |
| SCHEMBL8739260 | 0.90 | MEN1 (0.58) | MEN1KMT2AEZH2GLACYP2C9 | |
| SCHEMBL8739673 | 0.89 | MEN1 (0.62) | MEN1KMT2AEZH2GLACYP2C9 | |
| SCHEMBL8738911 | 0.81 | MEN1 (0.59) | MEN1KMT2AEZH2GLACYP2C9 | |
| SCHEMBL6119756 | 0.80 | EZH2 (0.77) | MEN1KMT2AEZH2 | |
| SCHEMBL6120920 | 0.79 | MEN1 (0.77) | MEN1KMT2AEZH2GLACYP2C9 | |
| SCHEMBL8738112 | 0.79 | EZH2 (0.79) | MEN1KMT2AEZH2GLA | |
| SCHEMBL8738618 | 0.78 | EZH2 (0.74) | MEN1KMT2AEZH2 | |
| SCHEMBL8739024 | 0.77 | EZH2 (0.69) | MEN1KMT2AEZH2L3MBTL1 | |
| SCHEMBL8739463 | 0.77 | EZH2 (0.73) | MEN1KMT2AEZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | MEN1 2650/4885KMT2A 84/4885EZH2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.